BELLA
DEAD

Serial Number

90639165

Owner

LivePerson, Inc.

Attorney

Kimberly S. Grimsley

Filing Date

Apr 12, 2021

Add to watchlist:

No watchlists yet
View on USPTO

BELLA Trademark

Serial Number: 90639165

BELLA is a trademark filed by LivePerson, Inc. on April 12, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

LivePerson, Inc. (177 trademarks)

665 Broadway, Suite 1200
New York, NY 10012

Entity Type: 03

Trademark Details

Filing Date

April 12, 2021

Registration Date

Not Registered

Published for Opposition

November 1, 2022

Goods & Services

Downloadable computer application software for mobile phones, namely, software for covid-19 and other infectious disease identification; Downloadable computer application software for computers, namely, software for covid-19 and other infectious disease identification; Downloadable mobile applications for health screenings relating to COVID-19 and other infectious disease; Downloadable mobile applications for tracking and reporting health conditions and symptoms; Scientific apparatus and instruments, namely, COVID-19 rapid tests for withdrawing and testing respiratory droplets for clinical, medical, research, and scientific purposes and parts and fittings thereof; Material testing apparatus and instruments, for identifying and testing pathogens and biomarkers in respiratory droplets for clinical, medical, research, and scientific purposes related to COVID-19 and other infectious diseases; Apparatus for transmission of communication; Monitoring, measuring, signaling and control apparatus and instruments for testing respiratory droplets against a panel of biomarkers for clinical, medical, research, and scientific purposes, namely, for COVID-19 and other infectious diseases

Diagnostic kits comprised of medical diagnostic assays for use in disease detection, screening, treating and monitoring, namely, monitoring COVID-19 and other infectious diseases; Respiratory rapid tests, namely, medical diagnostic assays for use in performing respiratory rapid tests related to COVID-19 and other infectious diseases; Medical diagnostic kits comprised of reagents and assays for use in disease detection, screening, treating and monitoring, including, monitoring COVID-19 and other infectious diseases and also including swabs, including nasal and throat swabs, and medical sample tubes; COVID-19 rapid tests comprising medical diagnostic reagents and assays for withdrawing and testing respiratory droplets and also including parts and fittings thereof

Healthcare services, namely, treatment of patients for infectious diseases or medical disorders; Medical and healthcare information, consultancy and advisory services relating to infections, viruses, SARS-CoV-2, COVID-19, and infectious, viral, communicable, blood borne pathogen, vector borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Providing a web site featuring medical information; Health care services, namely, disease management programs; Telehealth services, namely, providing telemedicine and services in conjunction with providing medical and healthcare services; Mobile healthcare services in the field of Covid-19 and other infectious disease testing, health assessments, intravenous infusion therapy, facilitating appointments; Medical screening services in the field of Covid-19 and other infectious diseases in a patient; Polymerase chain reaction (PCR) testing, rapid body antigen testing, and nucleic acid amplification testing for identifying and testing pathogens and biomarkers in respiratory droplets for medical diagnostic purposes related to COVID-19 and other infectious diseases

Medical instruments, namely, biosensors for detecting Covid-19 and other infectious diseases in a patient; Monitoring, measuring, signaling and control apparatus and instruments for testing respiratory droplets against a panel of biomarkers for medical diagnostic purposes, namely, for COVID-19 and other infectious disease

Providing temporary use of online non-downloadable software for use in the testing and diagnosis of COVID-19, coronavirus, and other diseases; Providing temporary use of online non-downloadable software for health screenings relating to COVID-19 and other infectious diseases and for tracking and reporting health conditions and symptoms; Providing temporary use of web-based software applications for health screenings relating to COVID-19 and other infectious diseases and for tracking and reporting health conditions and symptoms; Software as a service (SAAS) services featuring software for health screenings relating to COVID-19 and other infectious diseases and for tracking and reporting health conditions and symptoms; Electronic storage of information concerning persons infected with contagious disease for the purpose slowing or stopping the spread of the disease under the guidance of state and local public health departments, and information concerning physical sites visited by persons infected with contagious disease for the purpose slowing or stopping the spread of the disease under the guidance of state and local public health departments

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jan 29, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jan 29, 2024 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 6, 2023 EXRA
SOU EXTENSION 1 GRANTED
Jul 5, 2023 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 3, 2023 AITU
SOU EXTENSION 1 FILED
Jun 27, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 27, 2023 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 19, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 19, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 19, 2023 REAP
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 27, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 1, 2022 NPUB
PUBLISHED FOR OPPOSITION
Nov 1, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 12, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 29, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 21, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 21, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 21, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 21, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 1, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 31, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 31, 2022 TROA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 8, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 8, 2022 TCCA
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 8, 2022 COAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 1, 2021 GNRN
NON-FINAL ACTION E-MAILED
Dec 1, 2021 GNRT
NON-FINAL ACTION WRITTEN
Dec 1, 2021 CNRT
ASSIGNED TO EXAMINER
Nov 30, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 19, 2021 NWOS
NEW APPLICATION ENTERED
Apr 15, 2021 NWAP